Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

U.S. FDA panel rejects Johnson & Johnson drug for acute coronary syndrome-Reuters


Thursday, 16 Jan 2014 05:32pm EST 

Johnson & Johnson:Says that its anticoagulant Xarelto should not be approved to prevent further heart problems in patients who have recently suffered a heart attack, an advisory panel to the U.S. Food and Drug Administration concluded on Jan 16-Reuters.Says panel voted 10 to 0, with one abstention, that data presented by the company from a single clinical trial was not strong enough to justify approval, especially since some data from was missing.Says. 

Company Quote

91.31
-1.33 -1.44%
4 Sep 2015